A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)
A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin
This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.
調査の概要
状態
条件
詳細な説明
Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Dr PK Bhavani, MBBS., MPH., PGDBEME
- 電話番号:044 2836 9537
- メール:bhavani.pk@icmr.gov.in
研究連絡先のバックアップ
- 名前:Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- 電話番号:044 2836 9518
- メール:narendra.ng@icmr.gov.in
研究場所
-
-
Andhra Pradesh
-
Guntur、Andhra Pradesh、インド、522503
- 募集
- All India Institute of Medical Sciences(AIIMS), Mangalagiri
-
コンタクト:
- Dr S Sathiyanarayanan, MBBS., MD
- 電話番号:08645 280021
- メール:sathiya@aiimsmangalagiri.edu.in
-
-
Assam
-
Guwahati、Assam、インド、781101
- 積極的、募集していない
- All India Institute of Medical Sciences, Guwahati
-
-
Gujarat
-
Rajkot、Gujarat、インド、360001
- まだ募集していません
- Govt. PDU Medical College
-
コンタクト:
- Dr Bhoomika Patel, MBBS., MD
- 電話番号:0281 245 8337
- メール:doctorbhoomika@gmail.com
-
Surat、Gujarat、インド、395001
- 積極的、募集していない
- Govt. Medical College and NCH
-
-
Maharashtra
-
Mumbai、Maharashtra、インド、400008
- 募集
- Grant Govt. Medical College & Sir JJ Group of Hospitals
-
コンタクト:
- Dr Priti Meshram, MBBS., MD., DNB
- 電話番号:022 2373 5555
- メール:drpritimeshram@gmail.com
-
Nagpur、Maharashtra、インド
- まだ募集していません
- All India Institute Of Medical Sciences, Nagpur
-
コンタクト:
- Dr Yogesh Bahurupi, MBBS., MD
- 電話番号:0712 2352078
- メール:dr.yogeshab@gmail.com
-
-
Meghālaya
-
Shillong、Meghālaya、インド、793018
- 募集
- North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
-
コンタクト:
- Dr Monaliza Lyngdoh, MBBS., MD
- 電話番号:0364 2538013
- メール:monalizalyngdoh@gmail.com
-
-
National Capital Territory of Delhi
-
New Delhi、National Capital Territory of Delhi、インド、110030
- まだ募集していません
- National Institute of TB and Respiratory Diseases
-
コンタクト:
- Dr Jitendra Kumar Saini, MBBS., MD
- 電話番号:011 2651 3325
- メール:drsaini1973@gmail.com
-
-
Odisha
-
Bhubaneswar、Odisha、インド、751019
- 積極的、募集していない
- All India Institute of Medical Sciences (AIIMS), Bhubaneswar
-
Bhubaneswar、Odisha、インド、751001
- 積極的、募集していない
- Post Graduate Institute of Medical Education & Research, Capital Hospital
-
-
Tamil Nadu
-
Chennai、Tamil Nadu、インド、600031
- 募集
- ICMR - National Institute for Research in Tuberculosis
-
コンタクト:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
- 電話番号:044 2836 9537
- メール:bhavani.pk@icmr.gov.in
-
コンタクト:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- 電話番号:044 2836 9518
- メール:narendra.ng@icmr.gov.in
-
主任研究者:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
-
主任研究者:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
-
副調査官:
- Dr R Balaji, MBBS., MD.,
-
-
Telangana
-
Hyderabad、Telangana、インド、500038
- 募集
- Govt. General and Chest Hospital, Osmania Medical College
-
コンタクト:
- Dr V Karthik, MBBS., MD
- 電話番号:04083814421
- メール:vkarthikrao19@gmail.com
-
-
Uttar Pradesh
-
Agra、Uttar Pradesh、インド、282002
- 募集
- Sarojini Naidu Medical College
-
コンタクト:
- Dr Gajendra Vikram Singh, MBBS., MD
- 電話番号:0562 2260353
- メール:drsinghgv@gmail.com
-
Allahābād、Uttar Pradesh、インド、211002
- 募集
- Moti Lal Nehru Medical College
-
コンタクト:
- Dr Amitabh Das Shukla, MBBS., MD
- 電話番号:0532 261 3592
- メール:adshukla1977@gmail.com
-
Lucknow、Uttar Pradesh、インド、226003
- 募集
- King George Medical University
-
コンタクト:
- Dr Rajiv Garg, MBBS., MD
- 電話番号:0522 2255167
- メール:rajivkgmc@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Individuals aged equal or above 14 years.
- Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
- Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
- If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
- Willing to follow the trial procedures
Exclusion Criteria:
-
Body weight less than 30 kg in adults
-
Anti-TB treatment, >14 days for the current illness
-
Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA
-
Patients with serious forms of Extra-pulmonary TB
-
HIV Patients on second line ART regimens.
-
Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities
- ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
- Serum Creatinine >1.2 mg/dl.
-
Pregnant or lactating mothers
-
Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability
-
Patients with h/o of concomitant medications which may interfere with study drugs
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:2H R25 ZE /4 H R10 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
実験的:2 H R25 ZE/ 4 H R25 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
実験的:2 H R25 ZE L/2 H R25 E L
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg) Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin. |
Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs. |
|
アクティブコンパレータ:2 H R10 ZE /4H R10 E
Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol |
Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
時間枠:Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of patients with grade 3 or 4 adverse drug reactions.
時間枠:Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
時間枠:Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
時間枠:At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
|
|
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
時間枠:At 1st Month
|
At 1st Month
|
|
|
The cost effectiveness of different treatment regimens
時間枠:Through treatment completion, an average of 24 weeks
|
Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB. |
Through treatment completion, an average of 24 weeks
|
協力者と研究者
捜査官
- 主任研究者:Dr PK Bhavani, MBBS., MPH., PGDBEME、ICMR - National Institute for Research in Tuberculosis
- 主任研究者:Dr G Narendran, MBBS., DNB., DTRD., FRCP.,、ICMR - National Institute for Research in Tuberculosis
出版物と役立つリンク
一般刊行物
- Kannabiran BP, Arthanari J, Bhaskar A, Narayanan MKS, Inbaraj LR. Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis. Indian J Med Res. 2025 May;161(5):449-460. doi: 10.25259/IJMR_1673_2024.
- Perumal Kannabiran B, Palaniappan NA, Manoharan T, Paramasivam PK, Saini JK, Ansari MS, Jayabal L, Aggarwal AN, Garg R, Subramanyam B, Thakur D, Pantula S, P M R, Gs V, Natarajan S, Ammayappan RK, Manpreet B, Ganesan M, Angamuthu D, Chinnaiyan P, Singh M, Chandrasekaran P, Swaminathan S. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. Open Forum Infect Dis. 2024 Feb 2;11(3):ofae034. doi: 10.1093/ofid/ofae034. eCollection 2024 Mar.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- 2025 011
- CTRI/2026/02/102698 (レジストリ識別子:CLINICAL TRIALS REGISTRY - INDIA)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。